Suma  Krishnan net worth and biography

Suma Krishnan Biography and Net Worth

Suma M. Krishnan serves as Founder, Chief Operating Officer, Director of the Company. Ms. Krishnan has over two decades of experience in drug development. She previously served as Senior Vice President and head of the Human Therapeutics Division, as well as Senior Vice President of Regulatory Affairs at Intrexon Corporation (NYSE: XON) from 2012 to 2016. She previously served as Senior Vice President, Product Development at Pinnacle Pharmaceuticals, Inc. from 2009 to 2011. Ms. Krishnan served as Vice President, Product Development at New River Pharmaceuticals, Inc. from 2002 until 2007 (previously listed on Nasdaq prior to its acquisition by Shire plc in 2007). Prior to serving at New River Pharmaceuticals, Inc., Ms. Krishnan served in the following capacities: Director, Regulatory Affairs at Shire plc; Senior Project Manager at Pfizer, Inc. (NYSE: PFE), a multi-national pharmaceutical company; and a consultant at the Weinberg Group, a pharmaceutical and environmental consulting firm. Ms. Krishnan began her career as a discovery scientist for Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson (NYSE: JNJ), in May 1991. Ms. Krishnan received an M.S. in Organic Chemistry from Villanova University, an M.B.A. from Institute of Management and Research (India) and an undergraduate degree in Organic Chemistry from Ferguson University (India).

What is Suma Krishnan's net worth?

The estimated net worth of Suma Krishnan is at least $245.86 million as of March 11th, 2024. Ms. Krishnan owns 1,550,882 shares of Krystal Biotech stock worth more than $245,861,323 as of April 21st. This net worth approximation does not reflect any other investments that Ms. Krishnan may own. Additionally, Ms. Krishnan receives a salary of $789,920.00 as COO at Krystal Biotech. Learn More about Suma Krishnan's net worth.

How old is Suma Krishnan?

Ms. Krishnan is currently 59 years old. There are 2 older executives and no younger executives at Krystal Biotech. Learn More on Suma Krishnan's age.

What is Suma Krishnan's salary?

As the COO of Krystal Biotech, Inc., Ms. Krishnan earns $789,920.00 per year. The highest earning executive at Krystal Biotech is Mr. Krish S. Krishnan M.B.A., M.S., Founder, Chairman, President & CEO, who commands a salary of $1,070,000.00 per year. Learn More on Suma Krishnan's salary.

How do I contact Suma Krishnan?

The corporate mailing address for Ms. Krishnan and other Krystal Biotech executives is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. Krystal Biotech can also be reached via phone at (412) 586-5830 and via email at [email protected]. Learn More on Suma Krishnan's contact information.

Has Suma Krishnan been buying or selling shares of Krystal Biotech?

Suma Krishnan has not been actively trading shares of Krystal Biotech in the last ninety days. Most recently, Suma Krishnan sold 25,000 shares of the business's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $170.96, for a transaction totalling $4,274,000.00. Following the completion of the sale, the insider now directly owns 1,550,882 shares of the company's stock, valued at $265,138,786.72. Learn More on Suma Krishnan's trading history.

Who are Krystal Biotech's active insiders?

Krystal Biotech's insider roster includes Daniel Janney (Director), Krish Krishnan (CEO), Suma Krishnan (COO), Kathryn Romano (CAO), and Dino Rossi (Director). Learn More on Krystal Biotech's active insiders.

Are insiders buying or selling shares of Krystal Biotech?

In the last year, insiders at the sold shares 13 times. They sold a total of 279,680 shares worth more than $32,580,188.72. The most recent insider tranaction occured on March, 11th when insider Suma Krishnan sold 25,000 shares worth more than $4,274,000.00. Insiders at Krystal Biotech own 14.1% of the company. Learn More about insider trades at Krystal Biotech.

Information on this page was last updated on 3/11/2024.

Suma Krishnan Insider Trading History at Krystal Biotech

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/11/2024Sell25,000$170.96$4,274,000.001,550,882View SEC Filing Icon  
12/11/2023Sell25,000$105.67$2,641,750.001,574,206View SEC Filing Icon  
9/11/2023Sell25,000$127.23$3,180,750.001,599,206View SEC Filing Icon  
5/31/2023Sell25,000$116.16$2,904,000.001,624,206View SEC Filing Icon  
4/17/2023Sell25,000$87.65$2,191,250.001,649,206View SEC Filing Icon  
1/17/2023Sell22,148$80.77$1,788,893.961,680,115View SEC Filing Icon  
1/3/2023Sell1,700$80.33$136,561.001,706,201View SEC Filing Icon  
12/16/2022Sell10,527$80.10$843,212.701,715,913View SEC Filing Icon  
11/23/2022Sell4$80.01$320.041,787,718View SEC Filing Icon  
11/8/2022Sell823$80.04$65,872.921,726,440View SEC Filing Icon  
12/10/2021Sell100,000$70.50$7,050,000.00View SEC Filing Icon  
9/17/2020Sell50,000$46.37$2,318,500.001,871,629View SEC Filing Icon  
9/15/2020Sell15,952$46.30$738,577.601,871,629View SEC Filing Icon  
6/15/2020Sell50,000$43.50$2,175,000.001,928,486View SEC Filing Icon  
3/18/2020Sell659$40.20$26,491.801,948,903View SEC Filing Icon  
3/16/2020Sell2,559$40.14$102,718.261,948,903View SEC Filing Icon  
12/18/2019Sell9,112$61.84$563,486.081,994,089View SEC Filing Icon  
12/16/2019Sell20,947$63.56$1,331,391.321,994,089View SEC Filing Icon  
6/6/2018Buy25,000$11.02$275,500.00View SEC Filing Icon  
9/22/2017Buy100,000$10.00$1,000,000.001,935,249View SEC Filing Icon  
See Full Table

Suma Krishnan Buying and Selling Activity at Krystal Biotech

This chart shows Suma Krishnan's buying and selling at Krystal Biotech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Krystal Biotech Company Overview

Krystal Biotech logo
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Read More

Today's Range

Now: $158.53
Low: $155.91
High: $164.53

50 Day Range

MA: $159.74
Low: $108.01
High: $180.42

2 Week Range

Now: $158.53
Low: $82.09
High: $189.97

Volume

341,399 shs

Average Volume

250,610 shs

Market Capitalization

$4.52 billion

P/E Ratio

1,981.87

Dividend Yield

N/A

Beta

0.85